WHO Calls for Expressions of Interest in Developing Sabin-IPV

Safe and affordable inactivated polio vaccine for low-income countries.

One of the strategic priorities of the Global Polio Eradication Initiative is to enable low-income countries to produce Inactivated Polio Vaccine (IPV). To meet this objective,  the World Health Organization is working with academia, government and industry to develop an IPV  based on the non-infectious Sabin virus strain (sIPV). A range of manufacturers and research institutes have active programmes at various stages of development. The development and licensure of IPV produced from Sabin strains aims to reduce the number of manufacturing sites generating high volumes of high titre wild polioviruses for ”traditional” IPV production. Sabin polioviruses pose less of a threat in the event of an intentional or unintentional release from the production facility. This is a particular concern in low-income countries where the transmissibility of polioviruses is high.

Related


Related News

   27/06/2019
Research underway on a newer tool to protect children from polio and sustain a polio-free world
   10/05/2019
Decades-long polio infrastructure has spill-over benefits across larger public health interventions
   02/04/2019
JICA continues to support Pakistan in polio eradication efforts
   29/01/2019
Progress in the challenging last mile of eradication
   21/12/2018
Over 140 public health experts from 22 countries gather at the 6th Regional Meeting on Polio in Guatemala
   30/08/2018
By Roland Sutter, Research, Policy and Containment Team, Polio Eradication Department, WHO